Related Experiment Video
Updated: Aug 25, 2026

Human Pluripotent Stem Cell Based Developmental Toxicity Assays for Chemical Safety Screening and Systems Biology Data Generation
Published on: June 17, 2015
The US and European regulatory systems: a comparison
1Kathy.Redmond@tin.it
Abstract:
Regulatory agencies have a responsibility to ensure that high-quality safe, and effective medicines are made available to patients in a timely manner. Despite the fact that all regulators worldwide share the same aims, they do not adopt a consistent approach to drug approval, and as a result, medicines are often approved quicker in some countries than in others. There is a significant difference in cancer drug approval time between the US Food and Drug Administration and the European Medicines Evaluation Agency (EMEA; 304 versus 448 days). There are a number of reasons for this difference, not least the fact that EMEA appears to be much more conservative in its approach to fast-tracking the evaluation of promising cancer drugs. Increasing dialogue between the different stakeholder groups involved may help address this unsatisfactory situation.
Related Concept Videos
Drug Control Governance: Regulatory Bodies and Their Impact
Global Regulatory Systems
Drug Regulation
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
Drug Products: Biologics, Biosimilars and Interchangeables
Bioequivalence: Overview

